A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study

Covid19 Vaccine Clinical Trial

Official title:

A Phase II, Prospective, Open-Label, Single-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Sub-study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05038618
• Other study ID #: CT-COV-21s
• Status: Completed
• Phase: Phase 2
• Start date: August 2, 2021
• Est. completion date: March 11, 2022

Study information

• Verified date: October 2021
• Source: Medigen Vaccine Biologics Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This sub-study is a prospective open-label, single-center study to demonstrate comparability of different manufacturing scales.

Description:

In this sub-study, approximately 400 adults participants who are generally healthy or with stable pre-existing health conditions aged ≥ 20 to < 65 years will be enrolled. The first 250 participants enrolled in this sub-study will receive MVC-COV1901(Scale A) and the remains will receive MVC-COV1901(Scale B). Each participant will receive 2 doses of study intervention, administered 28 days apart via IM injection in the deltoid region, preferably of the nondominant arm, at Day 1 and Day 29. The study procedure and visit schedule refer to the main study protocol and will be the same as the study procedure for the Immunogenicity Subset.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 399
• Est. completion date: March 11, 2022
• Est. primary completion date: October 14, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 64 Years

Eligibility

Inclusion Criteria:

1. Male or female participant = 20 to < 65 years, or = 65 years of age at randomization.

2. Healthy adults or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study.

3. Female participant must:

1. Be either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal;

2. Or, if of childbearing potential, be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following the last injection of study intervention. Acceptable forms include:

i. Implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system ii. Established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository c. Have a negative pregnancy test

4. Participant is willing and able to comply with all required study visits and follow-up required by this protocol.

5. Participant has not travelled overseas within 14 days of screening and will not have any oversea travelling throughout the study period.

6. Participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.

Exclusion Criteria:

1. Pregnant or breast feeding or have plan to become pregnant in 30 days after last administration of study intervention.

2. Employees at the investigator's site, of the Sponsor or the contract research organization (CRO) directly involved in the conduct of the study.

3. Currently receiving or received any investigational intervention within 30 days prior to the first dose of study intervention.

4. Administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to the first dose of study intervention.

5. Administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the first dose of study intervention.

6. Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of study intervention.

7. Currently receiving or anticipate to receive treatment with tumor necrosis factor (TNF)-a inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of study intervention.

8. Major surgery or any radiation therapy within 12 weeks prior to the first dose of study intervention Medical Conditions

9. Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia.

10. A history of autoimmune disease (systemic lupus, rheumatoid arthritis, scleroderma, polyarthritis, thyroiditis, Guillain-Barré syndrome, etc.).

11. A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator).

12. Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy.

13. Human immunodeficiency virus (HIV) antibody positive participants with CD4 count < 350 cells/mm3 or a detectable HIV viral load within the past year (low level variations from 50-500 viral copies/mL or equivalent which do not lead to changes in antiretroviral therapy [ART] are permitted).

14. Hepatitis B surface antigen (HBsAg) positive participant with positive hepatitis B e antigen (HBeAg) or abnormal liver function.

15. Hepatitis C virus (HCV) antibody positive participants with detectable HCV ribonucleic acid (RNA) viremia in recent 12 weeks.

16. Participant with ongoing acute diseases or serious medical conditions which will interfere with adherence to study requirements, or the evaluation of any study endpoint. Acute diseases or serious medical conditions include cardiovascular (e.g. New York Heart Association Grade III or IV), pulmonary (e.g. chronic obstructive pulmonary disease stage III or IV), hepatic (e.g. Child-Pugh Class C), neurologic (e.g. dementia), metabolic (e.g. diabetes mellitus with hemoglobin A1c [HbA1c] > 8%), renal (Stage 3 or worse chronic kidney disease), psychiatric condition (e.g. alcoholism, drug abuse), current severe infections, medical history, physical findings, or laboratory abnormality that in the investigators' opinion are not in stable condition and participating in the study could adversely affect the safety of the participant.

Medigen Vaccine Biologics Corp. 34

17. Participant with previous known or potential exposure to SARS-CoV-1 or 2 viruses (EXCEPT for those who have been tested negative and completed the 14-day self-managements/ home quarantines/ home isolations) or received any other COVID-19 vaccine.

18. Participant with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901.

19. Body (oral, rectal, or ear) temperature = 38.0°C or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the first dose of study intervention.

Related Conditions & MeSH terms

• COVID-19
• Covid19 Vaccine

Intervention

Biological:
• MVC-COV1901(S protein with adjuvant)
Approximately 400 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Locations

Country	Name	City	State
Taiwan	Chang-Guang Memorial Hospital Lin-Kou	Taoyuan

Sponsors (1)

Lead Sponsor	Collaborator
Medigen Vaccine Biologics Corp.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of confirmed COVID-19 cases (Efficacy of MVC-COV1901)	To estimate the efficacy of MVC-COV1901, as compared to placebo, in the prevention of COVID-19 in terms of : The number of laboratory-confirmed COVID-19 cases occurring = 15 days after any dose of study intervention.; The number of laboratory-confirmed COVID-19 severe cases occurring = 15 days after any dose of study intervention.	Day 1 to 180 days after second vaccination
Other	Cell-mediated immune response of MVC-COV1901	To assess cell-mediated immune response of MVC-COV1901 as measured by intracellular cytokine staining (ICS) 28 days after the first dose of study intervention and 14 days after the second dose of study intervention; -The percentage of specific cytokine response	Day 1 to 14 days after second vaccination
Primary	Incidence of Adverse Event within 28 days post the second study intervention (Safety of MVC-COV1901)	To evaluate the safety and tolerability of MVC-COV1901 from Day 1 to 28 days after the second dose of study intervention in terms of the number and percentage of participants with the occurrence of: Solicited local AEs (up to 7 days after each dose of study intervention); Solicited systemic AEs (up to 7 days after each dose of study intervention); Unsolicited AEs (up to 28 days after each dose of study intervention); AE of Special Interest (AESI); Vaccine-Associated Enhanced Disease(VAED); Serious adverse events (SAEs)	Day 1 to 28 days after second vaccination
Primary	Immunogenicity of MVC-COV1901	To evaluate the immunogenicity of MVC-COV1901among different manufacturing scales in terms of neutralizing antibody titers 28 days after the second vaccination	Day 1 to 28 days after second vaccination
Secondary	Incidence of Adverse Event throughout study conduct (Safety of MVC-COV1901)	To evaluate the safety of MVC-COV1901 over the study period in terms of the number and percentage of participants with the occurrence of: >= Grade 3 AE; AE of Special Interest (AESI); Vaccine-Associated Enhanced Disease(VAED); Serious adverse events (SAEs)	Day 1 to 180 days after second vaccination
Secondary	Immunogenicity of MVC-COV1901	To evaluate the immunogenicity of MVC-COV1901 among different manufacturing scales in terms of antigen-specific immunoglobulin and neutralizing antibody titers 28 days after the first dose of study intervention, 14 days after the second dose of study intervention, 28 days after the second dose of study intervention and 180 days after the second dose of study intervention	Day 1 to 180 days after second vaccination